Results 41 to 50 of about 6,428 (208)

Rimonabant, Gastrointestinal Motility and Obesity [PDF]

Current Neuropharmacology, 2012
Obesity and overweight affect more than half of the US population and are associated with a number of diseases. Rimonabant, a cannabinoid receptor 1 blocker in the endocannabinoid (EC) system, was indicated in Europe for the treatment of obesity and overweight patients with associated risk factors but withdrawn on Jan, 2009 because of side effects ...
Sun, Yan, Chen, Jiande
openaire   +2 more sources

Parasomnias and sleep‐related movement disorders induced by drugs in the adult population: a review about iatrogenic medication effects

Journal of Sleep Research, Volume 34, Issue 2, April 2025.
Summary Parasomnias and sleep‐related movement disorders (SRMD) are major causes of sleep disorders and may be drug induced. The objective of this study was to conduct a systematic review of the literature to examine the association between drug use and the occurrence of parasomnias and SRMD.
Sylvain Dumont, Vanessa Bloch, Agnès Lillo‐Lelouet, Christine Le Beller, Pierre A. Geoffroy, Marc Veyrier   +5 more
wiley   +1 more source

Targeting Overweight and Obesity Phenotypes for Secondary Prevention of Cardiovascular Disease: A Call to Action for the Middle East and Beyond

Obesity Reviews, EarlyView.
ABSTRACT Although there are conflicting clinical data on the efficacy of weight reduction in reducing secondary events in patients with comorbid overweight and obesity (OAO) and cardiovascular disease (CVD), there is excellent epidemiological and biological evidence of a cause–effect relationship between OAO, CVD, and other systemic complications ...
Wael Almahmeed, Juan S. Barajas‐Gamboa, Mohammad Zubaid, Ebaa Al Ozairi, Abdullah Shehab, Khalid Al‐Rasadi, Charbel Abi Khalil, Noor Al Busaidi, Fahad Al Sindi, Zuhier Awan, Tomader Ali, Khaldoon Al‐Humood, Fatheya Al Awadi, Mohammed Al Hadad, Manal Al Kindi, Khalid Al Habib, Khalid Al Waili, Maryam Alsaeed, Adel Tash, Hani Sabbour   +19 more
wiley   +1 more source

Interfering with reconsolidation by rimonabant results in blockade of heroin-associated memory

Frontiers in Pharmacology
Drug-associated pathological memory remains a critical factor contributing to the persistence of substance use disorder. Pharmacological amnestic manipulation to interfere with drug memory reconsolidation has shown promise for the prevention of relapse ...
Jiang Lin, Yilin Peng, Jinlong Zhang, Jinlong Zhang, Junzhe Cheng, Junzhe Cheng, Qianqian Chen, Binbin Wang, Yuhang Liu, Shuliang Niu, Shuliang Niu, Jie Yan   +11 more
doaj   +1 more source

A novel chemical inhibitor suppresses breast cancer cell growth and metastasis through inhibiting HPIP oncoprotein

Cell Death Discovery, 2021
Increasing evidence suggests the pivotal role of hematopoietic pre-B-cell leukemia transcription factor (PBX)-interacting protein (HPIP/PBXIP1) in cancer development and progression, indicating that HPIP inhibition may be a promising target for cancer ...
Pengyun Li, Shengjie Cao, Yubing Huang, Yanan Zhang, Jie Liu, Xu Cai, Lulu Zhou, Jianbin Li, Zefei Jiang, Lihua Ding, Zhibing Zheng, Song Li, Qinong Ye   +12 more
doaj   +1 more source

The role of cannabinoid receptor 1 in the development of oxidative/nitrosative stress in mice with non-alcoholic fatty liver disease [PDF]

Medicinski Podmladak, 2019
Introduction: Non-Alcoholic Fatty Liver Disease (NAFLD) is hepatic manifestation of metabolic syndrome. It represents a spectrum of diseases ranging from steatosis, non-alcoholic steatohepatitis (NASH), that may progress to fibrosis, cirrhosis and ...
Brkić Dušan, Jorgačević Bojan
doaj  

Positron Emission Tomographic Imaging of the Cannabinoid Type 1 Receptor System with [C]OMAR ([C]JHU75528): Improvements in Image Quantification Using Wild-Type and Knockout Mice

Molecular Imaging, 2011
In this study, we assessed the feasibility of using positron emission tomography (PET) and the tracer [ 11 C]OMAR ([ 11 C]JHU75528), an analogue of rimonabant, to study the brain cannabinoid type 1 (CB1) receptor system.
Raúl Herance, Santiago Rojas, Sergio Abad, Xavier Jiménez, Juan Domingo Gispert, Olga Millán, Elena Martín-García, Aurelijus Burokas, Miquel Àngel Serra, Rafael Maldonado, Deborah Pareto   +10 more
doaj   +1 more source

Cannabinoid‐Inspired Fluorescent Boroisoquinolines for CB1 Receptor Imaging

ChemPhotoChem, Volume 10, Issue 9, September 2026.
A cannabinoid‐inspired fluorescent boroisoquinoline, a low‐micromolar partial agonist of the human CB1 receptor, enabled imaging of CB1 receptors by confocal microscopy in live cells. The intrinsic fluorescence of our probe provides a unique opportunity for CB1 imaging while keeping receptor structure and pharmacology similar to that observed with ...
Dénes Szepesi Kovács, Csilla Nierner, Bettina Szepesi Kovács, Attila Lehotzky, Edina Szűcs, András Dávid Tóth, Dóra Judit Kiss, László Hunyady, György M. Keserű, Péter Ábrányi‐Balogh   +9 more
wiley   +1 more source

Rimonabant ยาใหม่เพอื่ ลดความเสี่ยงในระบบหัวใจและเมแทบอลิก [PDF]

, 2008
การศึกษายาใหม่เพื่อป้องกันและรักษาโรคทางหัวใจและเมแทบอลิก (cardiometabolic diseases) ให้มีประสิทธิภาพดียิ่งขึ้นดำเนินต่อไป เพื่อลดปัจจัยเสี่ยงที่จะนำไปสู่การเกิด cardiometabolic diseases ยา rimonabant จัดเป็นยาตัวแรกในกลุ่ม cannabinoid1antagonist (CB1 ...
พันธุเวทย์, วิมล
core  

Prejunctional and peripheral effects of the cannabinoid CB1 receptor inverse agonist rimonabant (SR 141716) [PDF]

, 2008
Rimonabant is an inverse agonist specific for cannabinoid receptors and selective for their cannabinoid-1 (CB1) subtype. Although CB1 receptors are more abundant in the central nervous system, rimonabant has many effects in the periphery, most of which ...
Hester van Diepen, van Diepen, Hester, Eberhard Schlicker, Schlicker, Eberhard, Michel, Martin C., Martin C. Michel   +5 more
core   +1 more source